InMed Pharmaceuticals (INM) Asset Writedowns and Impairment (2022 - 2025)

InMed Pharmaceuticals has reported Asset Writedowns and Impairment for 4 years, with the latest figure at $208737.0 in Q4 2025.

• On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $208737.0 in Q4 2025; TTM through Dec 2025 was $208737.0, a N/A change from a year earlier, with the FY2025 full-year figure at $208737.0, down 31.74% from the prior year.
• Asset Writedowns and Impairment was $208737.0 for Q4 2025 at InMed Pharmaceuticals, roughly flat from $208737.0 in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $576772.0 in Q3 2022, with the low at -$267835.0 in Q2 2023.
• Average Asset Writedowns and Impairment over 4 years is $147460.4, with a median of $170474.0 recorded in 2023.
• The sharpest annual moves came in 2023 and 2025: Asset Writedowns and Impairment plunged 83.89% in 2023, then surged 392.21% in 2025.
• Over 4 years, Asset Writedowns and Impairment stood at $576772.0 in 2022, then plunged by 70.44% to $170474.0 in 2023, then slumped by 75.12% to $42408.0 in 2024, then surged by 392.21% to $208737.0 in 2025.
• The last three Asset Writedowns and Impairment figures came in at $208737.0 (Q4 2025), $208737.0 (Q2 2025), and $42408.0 (Q2 2024), per Business Quant data.